Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Central administration of GLP-1 and GIP decreases feeding in mice
Cherl NamKoong, Min Sun Kim, Byeong-Tak Jang, et al.
Biochemical and Biophysical Research Communications (2017) Vol. 490, Iss. 2, pp. 247-252
Open Access | Times Cited: 91

Showing 1-25 of 91 citing articles:

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan P. Frías, Michael A. Nauck, Joanna Van, et al.
The Lancet (2018) Vol. 392, Iss. 10160, pp. 2180-2193
Closed Access | Times Cited: 658
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coşkun, Kyle W. Sloop, Corina Loghin, et al.
Molecular Metabolism (2018) Vol. 18, pp. 3-14
Open Access | Times Cited: 575
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms, Matthew P. Coghlan, Kyle W. Sloop
Trends in Endocrinology and Metabolism (2020) Vol. 31, Iss. 6, pp. 410-421
Open Access | Times Cited: 277
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens, Emma K. Biggs, Tamana Darwish, et al.
Cell Metabolism (2019) Vol. 30, Iss. 5, pp. 987-996.e6
Open Access | Times Cited: 243
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr Mróz, Brian Finan, Vasily M. Gelfanov, et al.
Molecular Metabolism (2018) Vol. 20, pp. 51-62
Open Access | Times Cited: 175
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
Juan P. Frías, Michael A. Nauck, Joanna Van, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 6, pp. 938-946
Open Access | Times Cited: 164
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
Tito Borner, Caroline E. Geisler, Samantha M. Fortin, et al.
Diabetes (2021) Vol. 70, Iss. 11, pp. 2545-2553
Open Access | Times Cited: 107
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Qiyuan Keith Liu
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 16
Glucose-dependent insulinotropic polypeptide (GIP)
Timo D. Müller, Alice E. Adriaenssens, Bo Ahrén, et al.
Molecular Metabolism (2025) Vol. 95, pp. 102118-102118
Open Access | Times Cited: 2
Capsaicin has an anti-obesity effect through alterations in gut microbiota populations and short-chain fatty acid concentrations
Yuanwei Wang, Cheng Wei Tang, Yong Tang, et al.
Food & Nutrition Research (2020) Vol. 64
Open Access | Times Cited: 76
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion
Van B. Lu, Fiona M. Gribble, Frank Reimann
Nutrients (2021) Vol. 13, Iss. 3, pp. 883-883
Open Access | Times Cited: 66
Large-scale GWAS of food liking reveals genetic determinants and genetic correlations with distinct neurophysiological traits
Sebastian May-Wilson, Nana Matoba, Kaitlin H. Wade, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 48
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
Angelica Artasensi, Angelica Mazzolari, Alessandro Pedretti, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3094-3094
Open Access | Times Cited: 36
Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
Sudhir Pandey, Supachoke Mangmool, Warisara Parichatikanond
Pharmaceuticals (2023) Vol. 16, Iss. 6, pp. 836-836
Open Access | Times Cited: 26
Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease
Jonathan Q. Purnell, Carel W. le Roux
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. S2, pp. 3-12
Open Access | Times Cited: 9
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Joanna Michałowska, Ewa Miller‐Kasprzak, Paweł Bogdański
Nutrients (2021) Vol. 13, Iss. 2, pp. 351-351
Open Access | Times Cited: 49
The incretin/glucagon system as a target for pharmacotherapy of obesity
Stefano Del Prato, Baptist Gallwitz, Jens J. Holst, et al.
Obesity Reviews (2021) Vol. 23, Iss. 2
Open Access | Times Cited: 46
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity
Makoto Fukuda
Diabetes (2021) Vol. 70, Iss. 9, pp. 1929-1937
Open Access | Times Cited: 41
The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
Ali A. Rizvi, Manfredi Rizzo
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 1023-1030
Open Access | Times Cited: 37
Tremella fuciformis polysaccharide reduces obesity in high-fat diet-fed mice by modulation of gut microbiota
Gang He, Tangcong Chen, Lifen Huang, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 31
Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
Isabella Zaffina, Maria Chiara Pelle, Giuseppe Armentaro, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 18
The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Xiaoyu Lv, Hui Wang, Chongyang Chen, et al.
Diabetes Metabolic Syndrome and Obesity (2024) Vol. Volume 17, pp. 701-714
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top